NasdaqGS:SNDXBiotechs
How Revuforj’s Global Access Push At Syndax Pharmaceuticals (SNDX) Has Changed Its Investment Story
Syndax Pharmaceuticals recently highlighted ongoing commercial momentum for its oncology drugs Revuforj and Niktimvo and, earlier this month, presented at Guggenheim Securities’ Emerging Outlook: Biotech Summit 2026 in New York, led by CEO Michael A. Metzger.
The company also partnered with the World Orphan Drug Alliance to launch a Managed Access Program for Revuforj, widening international physician access in markets where the leukemia treatment is not yet commercially available.
Next,...